"Models, Economic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Statistical models of the production, distribution, and consumption of goods and services, as well as of financial considerations. For the application of statistics to the testing and quantifying of economic theories MODELS, ECONOMETRIC is available.
| Descriptor ID |
D018803
|
| MeSH Number(s) |
E05.318.740.500.600 E05.599.835.890 N05.715.360.750.530.500 N06.850.520.830.500.600
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Models, Economic".
- Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
- Investigative Techniques [E05]
- Epidemiologic Methods [E05.318]
- Statistics as Topic [E05.318.740]
- Models, Statistical [E05.318.740.500]
- Models, Economic [E05.318.740.500.600]
- Models, Theoretical [E05.599]
- Models, Statistical [E05.599.835]
- Models, Economic [E05.599.835.890]
- Health Care [N]
- Health Care Quality, Access, and Evaluation [N05]
- Quality of Health Care [N05.715]
- Health Care Evaluation Mechanisms [N05.715.360]
- Statistics as Topic [N05.715.360.750]
- Models, Statistical [N05.715.360.750.530]
- Models, Economic [N05.715.360.750.530.500]
- Environment and Public Health [N06]
- Public Health [N06.850]
- Epidemiologic Methods [N06.850.520]
- Statistics as Topic [N06.850.520.830]
- Models, Statistical [N06.850.520.830.500]
- Models, Economic [N06.850.520.830.500.600]
Below are MeSH descriptors whose meaning is more specific than "Models, Economic".
This graph shows the total number of publications written about "Models, Economic" by people in this website by year, and whether "Models, Economic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 3 | 3 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2018 | 0 | 2 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Models, Economic" by people in Profiles.
-
Ali AA, Kulkarni A, Bhattacharjee S, Diaby V. Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework. Pharmacoeconomics. 2024 Jul; 42(Suppl 2):211-224.
-
Chen Z, Cheng Y, DeRemer D, Diaby V. Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2021 Oct; 21(5):923-941.
-
Kozor R, Walker S, Parkinson B, Younger J, Hamilton-Craig C, Selvanayagam JB, Greenwood JP, Taylor AJ. Cost-Effectiveness of Cardiovascular Magnetic Resonance in Diagnosing Coronary Artery Disease in the Australian Health Care System. Heart Lung Circ. 2021 Mar; 30(3):380-387.
-
Spahillari A, Zhu J, Ferket BS, Hunink MGM, Carr JJ, Terry JG, Nelson C, Mwasongwe S, Mentz RJ, O'Brien EC, Correa A, Shah RV, Murthy VL, Pandya A. Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals. JAMA Cardiol. 2020 08 01; 5(8):871-880.
-
Wang CY, Pham PN, Kim S, Lingineni K, Schmidt S, Diaby V, Brown J. Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States. Clin Transl Sci. 2020 03; 13(2):352-361.
-
Tran JLA, Sheng R, Beaulieu A, Villodas M, McBurnett K, Pfiffner LJ, Wilson L. Cost-Effectiveness of a Behavioral Psychosocial Treatment Integrated Across Home and School for Pediatric ADHD-Inattentive Type. Adm Policy Ment Health. 2018 09; 45(5):741-750.
-
Okere AN, Ezendu K, Berthe A, Diaby V. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention. J Manag Care Spec Pharm. 2018 Feb; 24(2):142-152.
-
Boulin M, Diaby V, Tannenbaum C. Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada. PLoS One. 2016; 11(9):e0162951.
-
Diaby V, Ali AA, Adunlin G, Kohn CG, Montero AJ. Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. Curr Med Res Opin. 2016 06; 32(6):991-6.
-
Tannenbaum C, Diaby V, Singh D, Perreault S, Luc M, Vasiliadis HM. Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective. Drugs Aging. 2015 Apr; 32(4):305-14.